EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

AI-Assisted Pharmaceutical Formulation Design: Comparative Development and Experimental Evaluation of Sustained-Release Lornoxicam Tablets

Muthanna Abdulkarim iD, Waleed Bawazir, Arwa Alhaj Issa, Laian Tarboush iD, Amal Abbara, Gamal Mahrous iD, Adel Alghaith, Sally Almanasra, Khaled Suwais iD

Pharmaceuticals · 11.07.2026 · 19 (7) · 1070

DOI: 10.3390/ph19071070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 11.07.2026. Verfasst von Muthanna Abdulkarim und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, College of Pharmacy, Alfaisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia. Die Arbeit nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alfaisal University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: The integration of artificial intelligence (AI) into pharmaceutical development has the potential to accelerate early-stage formulation design. In this study, large language models (ChatGPT (GPT-4o, OpenAI) and DeepSeek (DeepSeek-R1, DeepSeek AI) were evaluated as supportive tools for the design of sustained-release lornoxicam matrix tablets. Using constrained formulation prompts and a predefined excipient space, each model generated candidate formulations intended for direct compression, with the objective of producing sustained-release systems capable of mimicking the dissolution behaviour of a commercial reference product (LOROX OD 16 mg).

Methods

The proposed formulations were prepared experimentally and evaluated for physicochemical properties, including weight variation, hardness, friability, and drug content, as well as in vitro dissolution performance over 24 h. Dissolution profiles were compared with the reference product using similarity (f2) and difference (f1) factors, and release behaviour was further characterized using kinetic models.

Results

All formulations demonstrated sustained-release behaviour without evidence of dose dumping. One ChatGPT-generated formulation (F3C) met the regulatory criteria for dissolution similarity to the reference product (f1 = 9.66, f2 = 71.31), while the remaining formulations showed variable release behaviour with f2 values ranging from 28.61 to 49.70. However, F3C exceeded the pharmacopeial friability limit marginally (1.108%), while DeepSeek formulations F5D and F6D exceeded pharmacopeial assay acceptance limits. Kinetic modelling indicated a range of transport mechanisms from anomalous diffusion to super Case II transport depending on polymer composition.

Conclusions

Although both AI systems successfully generated experimentally viable formulations, prediction accuracy analysis showed high trend-level correlations between AI-predicted and experimental dissolution profiles. However, the magnitude of quantitative error was substantial, with RMSE values exceeding 17% and MAPE values ranging from approximately 38% to 60%. These findings indicate that the models captured general release trends but did not provide reliable quantitative dissolution predictions.

Schlagwörter

Stichwörter der Autor:innen

ChatGPTDeepSeekdissolution kineticsextended-release matrix tabletsformulation designhydrophilic matrix systemslarge language modelslornoxicam

Autor:innen und Institutionen

  • Department of Pharmaceutical Sciences, College of Pharmacy, Alfaisal University, P.O. Box 50927, Riyadh 11533, Saudi Arabia.
  • Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia.
  • College of Computer and Information Sciences, Prince Sultan University, P.O. Box 66833, Riyadh 11586, Saudi Arabia.
  • Faculty of Computer Studies, Arab Open University, P.O. Box 84901, Riyadh 11681, Saudi Arabia.

ORCID-Profile: Muthanna Abdulkarim, Laian Tarboush, Gamal Mahrous, Khaled Suwais

Förderung

  • Alfaisal University

Zitieren

APA

Abdulkarim, M., Bawazir, W., Issa, A. A., Tarboush, L., Abbara, A., Mahrous, G., Alghaith, A., Almanasra, S., & Suwais, K. (2026). AI-Assisted Pharmaceutical Formulation Design: Comparative Development and Experimental Evaluation of Sustained-Release Lornoxicam Tablets. Pharmaceuticals, 19(7), 1070. https://doi.org/10.3390/ph19071070

Vancouver

Abdulkarim M, Bawazir W, Issa AA, Tarboush L, Abbara A, Mahrous G, et al. AI-Assisted Pharmaceutical Formulation Design: Comparative Development and Experimental Evaluation of Sustained-Release Lornoxicam Tablets. Pharmaceuticals. 2026;19(7):1070. doi:10.3390/ph19071070

BibTeX
@article{Abdulkarim2026,
  author = {Abdulkarim, Muthanna and Bawazir, Waleed and Issa, Arwa Alhaj and Tarboush, Laian and Abbara, Amal and Mahrous, Gamal and Alghaith, Adel and Almanasra, Sally and Suwais, Khaled},
  title = {AI-Assisted Pharmaceutical Formulation Design: Comparative Development and Experimental Evaluation of Sustained-Release Lornoxicam Tablets},
  journal = {Pharmaceuticals},
  year = {2026},
  volume = {19},
  number = {7},
  pages = {1070},
  doi = {10.3390/ph19071070}
}
Kostenlos starten →